Updated:
Lyell Immunopharma
Lyell Immunopharma is a asset manager based in South San Francisco; the Altss profile covers its classification, headquarters, registration, AUM band, and key...
Lyell Immunopharma
Learn about Lyell and how we are building an industry-leading clinical-stage pipeline of CAR-T cell product candidates for cancer.
General information
Firm type
Asset Manager
Location
Region
North America
Country
United States
City
South San Francisco
Corporate office
201 Haskins Way, Suite 101, South San Francisco, CA 94080, United States
Additional offices
Seattle, WA, United States · Bothell, WA, United States
Sector focus
Frequently asked questions
What is Lyell Immunopharma's lead clinical program?
Lyell's lead product candidate is rondecabtagene autoleucel, or ronde-cel, which is under evaluation in two pivotal clinical trials for patients with aggressive large B-cell lymphoma. The company's second candidate, LYL273, is in Phase 1 development for refractory metastatic colorectal cancer.
Does Lyell operate its own manufacturing capacity?
Yes. Lyell owns and operates the LyFE Manufacturing Center in Bothell, Washington. At full staffing, the facility can produce more than 1,200 patient CAR T-cell products per year, supporting both clinical trials and potential commercial launches.
What cancers does Lyell Immunopharma target?
Lyell focuses on both hematologic malignancies and solid tumors. In blood cancers, the goal is to improve outcomes over first-generation CAR T-cell therapies. For solid tumors, the firm is advancing cell therapy candidates, including LYL273 for metastatic colorectal cancer.
Where are Lyell Immunopharma's operations located?
The company is headquartered in South San Francisco, with a research office in Seattle and its dedicated manufacturing facility in Bothell, Washington. These three locations anchor its fully integrated research, development, and production model.
Is Lyell Immunopharma structured as a traditional investment firm?
No. Lyell is a clinical-stage biotechnology company with an integrated operational model — it controls therapy discovery, development, and proprietary manufacturing in-house. It is not structured as a family office, fund, or investment manager.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: